Angiotech/Study: In 7 Canadian Centers >T.ANP
Updated 5:09 AM ET November 16, 1999
Current quotes (delayed 20 mins.) TSE:ANP 12.00 0.10 (0.84%)
VANCOUVER (Dow Jones)--Angiotech Pharmaceuticals Inc. (T.ANP) said it has initiated a Phase II clinical study for the use of Micellar Paclitaxel in the treatment of patients with secondary progressive multiple sclerosis - a condition which has no approved treatment in the U.S.
In a press release, the company said the double-blind, placebo-controlled study plans to enroll 189 patients between the ages of 18 to 55. It said the nine-month study will be conducted at seven centers across Canada.
It said patients will receive placebo or Micellar Paclitaxel at two dose levels at four-week intervals for a total of six doses (with a 12-week follow-up period). It said the primary objective of the study will be to determine the difference in new lesion activity in the Micellar Paclitaxel treatment groups relative to the control group during the treatment phase.
Angiotech is a pharmaceutical company.
-John Moritsugu, Dow Jones Newswires; 416-306-2100